Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000374 · ClinicalTrials.gov registry record · Phase 4
Treatment for First-Episode Schizophrenia
A Phase 4 study of Schizophrenia, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 125
- Enrollment target
- 2
- Study locations
NCT00000374 is a Phase 4 study of Schizophrenia that has completed, run by Northwell Health. The registered enrollment target is 125 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (43% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00000374, a Phase 4 study of Schizophrenia, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 125 participants
- Enrollment target
- 2
- Study locations
Study Summary
This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
Conditions Studied
Interventions
- DRUG Risperidone
- DRUG Olanzapine
Study Locations (2)
New York
- Hillside Hospital - Glen Oaks
- Bronx-Lebanon Hospital Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 1998-09 |
| Est. Completion | 2007-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000374
The ClinicalTrials.gov registry entry for NCT00000374 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (43% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Risperidone is the first listed.
NCT00000374 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00000374 about?
NCT00000374 is a clinical study titled "Treatment for First-Episode Schizophrenia". This 3-year study will determine if the antipsychotic medications olanzapine (Zyprexa®) and risperidone (Risperdal®) can help patients with first-episode schizophrenia.
What is the current status of trial NCT00000374?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 125 participants. The study started on 1998-09. Estimated completion is 2007-05.
What conditions does trial NCT00000374 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00000374?
The interventions under investigation include: Risperidone (DRUG), Olanzapine (DRUG).
Who is sponsoring clinical trial NCT00000374?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000374 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.